Since the activity of the former pathways influences CD86 expression, increased CD86 expression in ibrutinib‐resistant cases indicates the recovery of the BCR pathway; thus, it can be a suitable marker for monitoring ibrutinib resistance in CLL cells. The gene discussed is CD86; the disease is B-cell chronic lymphocytic leukemia.